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Correlates of acute renal failure in patients receiving parenteral Serious fungal infections remain an important clinical
amphotericin B. problem, and despite recent advances, they carry high mor-
Background. While parenteral amphotericin B is an effec- bidity and mortality [1, 2]. Amphotericin B has long beentive therapy for serious fungal infections, it frequently causes
the primary agent for treatment of these infections, al-acute renal failure (ARF). This study identified correlates of
though it carries a substantial risk of toxicity, especiallyARF in amphotericin B therapy and used them to develop clin-
ical prediction rules. nephrotoxicity [3–8]. Amphotericin B-associated neph-
Methods. All 643 inpatients receiving parenteral amphoteri- rotoxicity is characterized by nonoliguric ARF due to acute
cin B therapy at one tertiary care hospital were included. Data tubular necrosis. It is frequently accompanied by hypo-regarding correlates were obtained both electronically and
kalemia, hypomagnesemia, and a nonanion gap metabolicfrom manual chart review in a subsample of 231 patients. ARF
acidosis, and less often by hypernatremia due to nephro-was defined as a 50% increase in the baseline creatinine with
a peak 2.0 mg/dL. genic diabetes insipidus [3–8].
Results. Among 643 episodes, ARF developed in 175 (27%). Relatively few empiric data are available about risk
In the larger group, the only independent correlate of ARF factors for amphotericin-induced ARF [9, 10], and no clin-was male gender (OR 2.2, 95% CI, 1.5 to 3.3). In the subsam-
ical prediction rule is available. In a case-control studyple (N  231), independent correlates of ARF were maximum
of 35 cases of renal failure associated with amphotericindaily amphotericin dosage, location at the time of initiation of
amphotericin therapy, and concomitant use of cyclosporine. by Fisher et al [9], independent risk factors for amphoter-
These data were used to develop two clinical prediction rules. A icin nephrotoxicity included amphotericin dose, patient
rule using only data available at initiation of therapy stratified weight, diuretic use during amphotericin B therapy, andpatients into groups with probability of ARF ranging from 15
abnormal baseline creatinine. A more recent study byto 54%, while a rule including data available during therapy
Luber et al of 178 patients receiving amphotericin B(maximum daily dose) stratified patients into groups with prob-
ability of ARF ranging from 4 to 80%. used a variety of definitions of nephrotoxicity [10]. The
Conclusions. Acute renal failure occurred in a quarter of the findings from this study indicated that the cumulative
patients. Correlates of ARF at the beginning and during the dose of amphotericin B and receipt of concomitantcourse of amphotericin therapy were identified and then com-
nephrotoxins were independent risk factors for all defi-bined to allow stratification according to ARF risk. These data
nitions, while cyclosporine therapy was the strongest cor-also provide evidence for guidelines for the selection of patients
for alternative therapies. relate of severe nephrotoxicity.
Other drugs including liposomal amphotericin prepa-
rations [11, 12] and imidazoles [1] have recently become
available for treatment of serious fungal infections. The
limited available data suggest that liposomal amphoteri-
cin preparations are less nephrotoxic [11]. There is less
experience with these agents, although there is no defini-Key words: clinical prediction rule, nephrotoxicity, adverse drug events,
quality of care, iatrogenic injury, fungal infection, acute tubular necrosis. tive evidence that they are individually or collectively
more or less effective than conventional therapy with am-Received for publication November 28, 2000
photericin B. Therefore, a principal issue with the use ofand in revised form March 19, 2001
Accepted for publication April 30, 2001 these preparations has been that they are very expensive.
Providers and health care organizations have had to 2001 by the International Society of Nephrology
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make decisions about what criteria to use for treatment reviews were performed on a sample of 231 of these pa-
tients. To obtain this sample, a random number genera-with these expensive agents. The majority of guidelines
tor was used to randomly draw 200 from the 348 patientsdeveloped have placed restrictions of the use of alterna-
admitted between November 17, 1994, and October 15,tive agents, usually based on the patient’s baseline serum
1996; patients were preferentially selected from this pe-creatinine concentration. Evidence in support of these
riod because more electronic data were available. Amongguidelines is limited.
this sample, 9% of charts were unavailable, leaving 182To gain insight into the use of newer, more expensive
patients. To enrich the group for the presence of ARF,but less nephrotoxic agents, this study had the following
all 23 remaining patients who developed ARF from thosegoals: (1) to determine the incidence of amphotericin-
admitted after November 17, 1994 and a random sampleinduced nephrotoxicity; (2) to describe a subset of the
of an additional 26 patients who developed ARF fromstudy group in detail available from chart review; (3)
the earlier period were included. Among the 231 pa-within the subgroup, to identify univariate correlates
tients, 39 met the criteria for severe ARF and 52 met theof ARF in patients receiving amphotericin, to identify
criteria for significant ARF. The proportion of patientsindependent correlates of this complication; and (4) to
developing ARF did not change significantly over thedevelop and validate clinical prediction rules stratifying
years of the study (P  0.20).patients according to their risk of nephrotoxicity.
Data collection
METHODS For all patients, data were obtained from both hospital
billing and clinical databases, and for a subset of 231Study site
patients, additional data were collected from chart re-The study was performed at Brigham and Women’s
view. Baseline, final, and highest creatinine values wereHospital, a 700-bed tertiary care hospital that is a major
obtained as described elsewhere [2]. Demographic andteaching hospital of Harvard Medical School. It has ap-
other data including age, gender, race, insurance statusproximately 35,000 admissions annually. The hospital
(classified as fee-for-service, health maintenance organi-has a large oncology service and a bone marrow trans-
zation, Medicare, Medicaid, and none), total dose of am-plantation unit. The study was approved by the hospital’s
photericin B therapy, concomitant medications includingHuman Research Committee.
nonsteroidal antiinflammatory drugs, diuretics, amino-
glycosides and cyclosporine, and discharge diagnosis-Main outcome measures
related group (DRG) were collected from the hospital’s
Acute renal failure was defined as a 50% increase in clinical database. To adjust for severity of illness, year-
baseline creatinine with a peak2.0 mg/dL. In secondary specific DRG weight was used [13].
analyses, acute renal failure was divided into categories: In addition, charts were reviewed to collect additional
severe, defined as a doubling of baseline creatinine val- clinical information, including whether the patient was
ues with a peak  3.0 mg/dL, and significant, meeting receiving amphotericin therapy at the time of admission;
the definition for ARF but not the definition for severe the starting, maximum daily, and cumulative doses of
renal failure. amphotericin as well as days of therapy; the clinical ser-
We also report the proportion of episodes in which vice at time of admission (medical or surgical); the unit
metabolic abnormalities developed; in each case, the type on beginning amphotericin (general care unit vs.
classification was made based on the worst result during intermediate care unit or intensive care unit (ICU); the
the episode. Hypokalemia was defined as severe if the indication for initiation of amphotericin therapy (docu-
serum potassium was 3 mg/dL and significant if it was mented fungus in blood, urine, tissue or cerebrospinal
3 to 3.4 mg/dL. Hypomagnesemia was considered severe fluid; documented fungus in sputum or other non-sterile
if the serum magnesium was 1 mg/dL and significant site; or empiric therapy for fever and neutropenia or
if it was 1 to 1.7 mg/dL. other); major underlying disease; mean Charlson comor-
bidity score [14] (both with and without AIDS, since
Study population AIDS patients were much less likely to develop ARF
All 1192 adults admitted between May 17, 1993, and but receive a high score on the Charlson index); presence
April 22, 1997, who received amphotericin B were eligi- of bone marrow or lung transplantation; and baseline
ble [2]. Admissions were excluded if the patient was on laboratory data including blood urea nitrogen, potas-
dialysis before beginning therapy (N  52), if liposomal sium, bicarbonate, total bilirubin, albumin, magnesium,
amphotericin B was given (N  64), or if amphotericin leukocyte count, hemoglobin, and platelet count.
B was given by a nonparenteral route (that is, bladder
Analysesirrigation, N  433). Altogether, there were 643 admis-
sions in which intravenous amphotericin B therapy was Univariate comparisons were made using the Wil-
coxon rank-sum statistic and the chi-square statistic.given. To obtain additional clinical information, chart
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Table 1. Study patient characteristics in the entire cohort and subset
All Subset
(N643) (N231)
Mean age (SD) years 47 (15) 48.1 (14.0)
Female N (%) 260 (40.4) 73 (31.6)
Nonwhite N (%) 110 (17.1) 31 (13.4)
Uninsured or Medicaid N (%) 118 (18.4) 34 (14.7)
Total dose of amphotericin g
Mean (SD) 0.87 (1.05) 0.91 (1.18)
Median (25th, 75th percentiles) 0.6 (0.35, 1.05) 0.55 (0.3, 1.05)
Serum creatinine mg/dL
Mean (SD) 1.1 (0.6) 1.2 (0.5)
Median (25th, 75th percentile) 1 (0.8, 1.3) 1 (0.8, 1.4)
1.5, N (%) 99 (15.4) 35 (15.2) Fig. 1. Percent of patients developing acute renal failure (ARF), hypo-
Final kalemia, and hypomagnesemia. ARF was defined as a doubling of the
Mean (SD) 1.6 (0.9) 1.8 (0.9) baseline blood creatinine with a peak 3.0 mg/dL (severe) or 50%
Median (25th, 75th percentiles) 1.3 (1, 1.8) 1.5 (1.1, 2.0) increase in the baseline creatinine with a peak2.0 mg/dL (significant).
Highest Hypokalemia was defined as serum potassium (mg/dL) 3 (severe), or
Mean (SD) 2.0 (1.2) 2.2 (1.2) 3 to 3.4 (significant). Hypomagnesemia was defined as serum magnesium
Median (25th, 75th percentiles) 1.7 (1.3, 2.3) 1.9 (1.4, 2.6) (mg/dL) 1 (severe) or 1 to 1.7 (significant). Symbols are: () severe;
Diagnosis-related group weight () significant; ( ) normal.
Mean (SD) 6.3 (5.9) 5.9 (5.7)
Median (25th, 75th percentiles) 3.6 (1.7, 14.4) 3.5 (1.7, 11.7)
Deceased N (%) 164 (25.5) 41 (17.7)
Table 2. Fungi species and means of documentation during
admission in the subset
Subset
Multivariable analyses were performed using logistic re- (N231)
gression, with ARF as the primary outcome of interest. Species, N (%)
We developed two models for development of ARF, one Candida 59 (25.5)
Aspergillus 38 (16.5)including only variables known at initiation of amphoter-
Mold or yeasta 4 (1.7)icin therapy, the second including in addition variables Cryptococcus or other 17 (7.4)
that became available during the course of therapy. All None isolated 115 (49.8)
Means of documentation, N (%)variables were included in the baseline models with P
Positive culture 69 (29.9)values less than 0.10 in the univariate analyses. Stepwise Pathology 34 (14.7)
logistic regression was used to identify correlates of Other 13 (5.6)
None 115 (49.8)ARF, and variables were retained using a threshold of
a Including Torulopsis, Mucor and MalasseziaP  0.05. To develop clinical prediction rules, points
were assigned to the beta coefficients from the multivari-
ate models [15]. Goodness-of-fit was assessed using the
Hosmer-Lemeshow statistic. To adjust for the sampling
dian 0.6 g, interquartile range 0.35 to 1.05 g) of am-
scheme and back extrapolate to our initial population,
photericin B. The mean baseline creatinine was 1.1 
the individual cases were weighted according to their
0.6 mg/dL, and the mean final creatinine was 1.6 sampling fraction. The bootstrap method was used to
0.9 mg/dL. Among these 643 admissions, ARF occurredvalidate the selection of correlates in the models (100
in 175 (27%). This ARF met our criteria for severe ARFsamples) and the predictive ability of the models (200
in 67 episodes (10%), while it was significant in the re-samples) [16]. Briefly, the bootstrap constructs alterna-
maining 108 (17%). We also evaluated the frequencytive analytic cohorts by sampling the study population
that hypokalemia and hypomagnesemia occurred amongwith replacement and refitting the regression models.
the subsample of 231 patients for whom detailed dataWith this methodology, one can determine the stability
were collected (Fig. 1). Of these complications, hypoka-of the models’ effect estimates (in this case, the odds
lemia was the most frequent, and approximately oneratio of developing ARF). All analyses were performed
third of patients had their lowest potassium value belowusing SAS [17].
3.0 mg/dL, whereas another third had significant hypo-
kalemia (3.5 mg/dL) at some time during their course.
RESULTS A specific fungus was identified in approximately half
the patients receiving amphotericin B (Table 2); in theAltogether, there were 643 admissions included in
remainder of episodes, therapy was given empiricallywhich patients received parenteral amphotericin B (Ta-
but no infection was documented. In 25.5% of episodes,ble 1). Patients had a mean age of 47, were predomi-
nantly white, and received a mean of 0.87  1.05 g (me- Candida species were identified, while Aspergillus spe-
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Table 3. Univariate correlates of acute renal failure (ARF) in the entire cohort and subset
Entire cohort Subset
ARF Normal ARF Normal
(N175) (N468) P value (N91) (N140) P value
Age, mean (SD) years 45.9 (13.8) 46.9 (15.2) 0.383 46.0 (11.3) 49.5 (14.3) 0.049
Female N (%) 49 (28.0) 211 (45.1) 0.001 25 (27.5) 48 (34.3) 0.276
Amphotericin B, mean (SD)
Days of therapya 14.0 (15.6) 8.0 (8.3) 0.0001 11.4 (11.1) 7.4 (8.4) 0.0001
Days until peak creatinineb 16.5 (17.2) 9.7 (11.1) 0.0001 14.2 (16.2) 9.3 (12.7) 0.0001
Amphotericin total dose N (%)
0.5 g 57 (32.6) 201 (43.0) 32 (35.2) 66 (47.5)
0.5–1.0 g 57 (32.6) 151 (32.3) 30 (33.0) 39 (28.1)
1.0–1.5 g 28 (16.0) 62 (13.2) 0.051 12 (13.2) 15 (10.8) 0.098
1.5–2.0 g 16 (9.1) 29 (6.2) 5 (5.5) 12 (8.6)
2.0 g 17 (9.7) 25 (5.3) 12 (13.2) 7 (5.0)
Baseline creatinine mean (SD) mg/dL 1.2 (0.7) 1.1 (0.6) 0.027 1.1 (0.5) 1.2 (0.5) 0.965
Baseline creatinine 1.5 N (%) 28 (16.0) 71 (15.2) 0.795 11 (12.1) 24 (17.1) 0.295
DRG weight, mean (SD) g 7.5 (6.2) 5.8 (5.7) 0.0002 7.8 (6.2) 4.8 (5.1) 0.0005
DRG is diagnosis-related group.
a Between the start and the date of peak creatinine or stopping amphotericin, whichever came first
b Between the start date and the creatinine peak date
cies were next most frequent at 16.5%. The most fre- and days of amphotericin therapy, DRG weight, and loca-
tion in ICU or intermediate care on beginning amphoter-quent means of documentation was positive culture
(29.9%), followed by tissue pathology (14.7%). icin therapy (Tables 3 and 4). Other weaker correlates
(P  0.05) included younger initial age, higher initialThe frequency of ARF was evaluated by amount of
amphotericin given among the large cohort of 643 admis- weight, lower Charlson score when AIDS was included
(although this was no longer significant when AIDS wassions. The frequency of ARF increased by the total
amount of amphotericin given (Ptrend  0.002). The pro- excluded) and higher initial potassium level. Mean base-
line creatinine and baseline creatinine 1.5 mg/dL wereportion of patients with ARF ranged only from 22% in
the group receiving0.5 g to 40% in the group receiving not correlated with development of ARF nor was the
presence of aspergillus or mold infection.the highest category of amphotericin B (2.0 g).
Univariate correlates of acute renal failure Multivariate correlates of acute renal failure
In multivariate analyses, the only significant correlatesUnivariate correlates of ARF in variables available in
both the entire cohort and the subset (Table 3) were of development of ARF available at initiation of ampho-
tericin therapy were location in an ICU or intermediatemale gender (significant in the larger group at P 0.001,
but not in the subgroup at P  0.276, although the trend care unit on beginning amphotericin B (OR 2.4, 95%
CI, 1.4 to 4.4), and concomitant use of cyclosporine (ORwas similar), days of amphotericin therapy (P  0.0001
for both groups), and days until peak creatinine (P  2.6, 95% CI, 1.5 to 4.8; Table 5). In a model including
additional variables available during the course of ther-0.0001 for both groups).
Within the subgroup, additional descriptive data were apy, the same variables remained correlated with similar
odds ratios, and in addition maximum daily amphotericinavailable from chart review (Table 4). Almost 8% of
patients were receiving amphotericin at admission to the dosage was an independent correlate (for dose of 30 to
59 mg, OR 4.0, 95% CI, 1.3 to 12.6; for dose 60 mg,hospital; 85.7% of patients were on the medical service.
Approximately half were on general care units, and half OR 8.8, 95% CI, 2.6 to 29.4).
were in ICUs or intermediate care. The predominant in-
Clinical prediction rulesdication for amphotericin use was empiric, and in only
16% of cases was a documented positive culture avail- These data were used to create clinical prediction rules
to predict development of ARF; the first rule includedable from a normally sterile site at onset of therapy.
Over half the patients had leukemia or myeloma as their only variables available at initiation of therapy, and the
second also included variables available during theprimary underlying condition, and 69% were immuno-
suppressed. Organ transplantation was common: 34% course of therapy (Table 5). All cases were weighted
according to sampling fraction. In the first model, cyclo-had undergone prior bone marrow transplantation, and
11% had undergone lung transplantation. sporine therapy and location in intermediate unit or ICU
at amphotericin initiation were each assigned one point.In this subset, the strongest univariate correlates of
ARF (P 0.001) were maximum daily amphotericin dose In the second model, amphotericin dosage of 30 to 59 mg
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Table 4. Univariate correlates of acute ranal failure (ARF) in the subset
Total ARF Normal
(N231) (N91) (N140) P value
Patient weight,a mean (SD) kg 74.8 (16.8) 77.0 (15.4) 73.3 (17.6) 0.044
Amphotericin B, mean (SD)
Starting dose mg 35.0 (25.0) 36.1 (14.7) 34.2 (29.9) 0.007
Maximum daily dose mg 51.9 (29.3) 59.3 (23.0) 47.1 (32.0) 0.0001
On amphotericin at admission N (%) 18 (7.8) 3 (3.3) 15 (10.7) 0.04
Service at amphotericin start N (%)
Medical 198 (85.7) 74 (81.3) 124 (88.6)
0.124Surgical 33 (14.3) 17 (18.7) 16 (11.4)
Location at amphotericin start N (%)
Ward 126 (54.6) 34 (37.3) 92 (65.7)
0.001Intermediate  ICU 105 (45.4) 57 (62.6) 48 (34.3)
Indication for amphotericin use N (%)
Empiric therapy for fever, neutropenia or other 146 (64.3) 56 (61.5) 90 (64.2)
0.672Documentation of fungus 85 (36.8) 35 (38.5) 50 (35.7)
In blood, urine, tissue or CSF 37 (16.0) 12 (13.2) 25 (17.9)
In sputum or other 48 (20.8) 23 (25.3) 25 (17.9)
Underlying disease N (%)
Immunosuppression 159 (68.8) 69 (75.8) 90 (64.3) 0.064
Leukemia or myeloma within 6 months 131 (56.7) 50 (55.0) 81 (57.9) 0.662
Chronic obstructive pulmonary disease 36 (15.6) 14 (15.4) 22 (15.7) 0.946
Non-Hodgkin’s lymphoma within 6 months 25 (10.8) 7 (7.7) 18 (12.9) 0.217
AIDS 23 (10.0) 3 (3.3) 20 (14.3) 0.006
Diabetes mild to moderate 22 (9.5) 10 (11.0) 12 (8.6) 0.541
Moderate or severe renal diseaseb 7 (3.0) 3 (3.3) 4 (2.9) 0.849
Any of leukemia, Hodgkin disease, non-Hodgkin’s
lymphoma or metastatic solid tumor 162 (70.1) 65 (71.4) 97 (69.3) 0.728
Lab results, baseline mean (SD)
BUN mg/dL 24.1 (18.1) 25.8 (18.7) 23.1 (17.7) 0.077
Potassium mmol/L 4.0 (0.6) 4.2 (0.5) 3.9 (0.6) 0.002
Baseline creatinine clearance 60c N (%) 53 (24.4) 16 (18.8) 37 (28.0) 0.123
Charlson score including AIDS, mean (SD) 3.0 (2.6) 2.4 (1.5) 3.4 (3.0) 0.004
Charlson score without AIDS, mean (SD) 2.4 (1.9) 2.2 (1.4) 2.5 (2.1) 0.230
Organ transplant N (%)
Bone marrow 79 (34.2) 42 (46.2) 37 (26.4) 0.002
Lung 26 (11.3) 14 (15.4) 12 (8.6) 0.109
Immunosuppressive therapy N (%)
Steroids 96 (41.6) 44 (48.4) 52 (37.1) 0.091
Cyclosporine 80 (34.6) 47 (51.7) 33 (23.6) 0.001
Fatality of underlying diseased N (%)
Rapidly 24 (10.4) 9 (9.9) 15 (10.7)
Ultimately 127 (55.0) 42 (46.1) 85 (60.7) 0.052
Nonfatal 80 (34.6) 40 (44.0) 40 (28.6)
Present surgery N (%) 116 (50.2) 53 (58.2) 63 (45.0) 0.049
Nephrotoxic agents N (%)
Aminoglycosides 151 (65.4) 65 (71.4) 86 (61.4) 0.119
Diuretics 34 (14.7) 12 (13.2) 22 (15.7) 0.596
ACE inhibitors 11 (4.8) 7 (7.7) 4 (2.9) 0.092
On intravenous lipid during amphotericin course N (%) 65 (28.1) 36 (39.6) 29 (20.7) 0.002
Candida species positive N (%) 59 (25.5) 28 (30.8) 31 (22.1) 0.142
Abbreviations are: ICU, intensive care unit; CSF, cerebrospinal fluid; ACE, angiotensin-converting enzyme. Variables with P  0.10 or primary interest are shown.
a Data availabale from 85 ARF and 132 normal patients
b Defined as patients with serum creatinine 3.0 mg/dL but no status post-kidney transplantation
c Creatinine clearance (CCr)  (140  age)  weight  0.85 if female/(72  baseline serum creatinine)
d Defined as predicted chance of fatality within one month greater than 50% due to any underlying disease, predicted chance of fatality within 5 years greater
than 50% due to underlying disease, and no fatal underlying disease [18]
was assigned three points, and dosage of 60 mg was of ARF of 28%, and a high-risk group with 24% of
patients with a risk of ARF of 54% (Table 6). The modelfive points. The location in an ICU or intermediate care
unit was assigned two points, and cyclosporine use was for use during therapy provided more separation ac-
cording to risk, with a very-low risk group, includinggiven two points.
The model for use at initiation of therapy stratified 12% of patients with an ARF risk of 4%, a low-risk
group including 27% of patients with an ARF risk ofpatients into three groups, including a low-risk group
with 44% of all patients with a risk of ARF of 15%, an 13%, an intermediate-risk group including 51% of pa-
tients with a risk of ARF of 33%, and a high-risk groupintermediate-risk group with 32% of patients with a risk
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Table 5. Independent predictors of acute renal failure (ARF) identified by multivariate analyses
Variable 	 (SE) Odds ratio 95% CI Pointsc
Model for amphotericin beginninga
Intercept 3.08 (0.55)
Location in intermediate unit or ICU at
amphotericin initiation 0.89 (0.30) 2.4 1.4–4.4 1
On cyclosporine 0.97 (0.31) 2.6 1.5–4.8 1
Model for during amphotericin courseb
Intercept 4.40 (0.08)
Location in intermediate care unit or ICU at
amphotericin initiation 0.80 (0.31) 2.2 1.2–4.1 2
On cyclosporine 0.96 (0.32) 2.6 1.4–4.9 2
Maximum daily amphotericin dose
30–59 mg 1.39 (0.59) 4.0 1.3–12.6 3
60 mg 2.17 (0.62) 8.8 2.6–29.4 5
ICU is intensive care unit. Variables in both baseline models are age at admission, location at amphotericin initiation, AIDS, baseline blood urea nitrogen (BUN),
baseline potassium, bone marrow transplantation, on steroid therapy, on cyclosporine therapy, classification of fatality of underlying disease, present surgery, on
angiotensin-converting enzyme inhibitors
a Baseline model also includes amphotericin starting dose
b Baseline model also includes days on amphotericin before serum creatinine reaching the peak, total dose of amphotericin, maximum daily amphotericin dose,
on intravenous lipid therapy
c Assigned by dividing 	 coefficients by the appropriate denominator to get integer scores [15]
Table 6. Performance of the prediction rules for acute renal failure (ARF)
Risk score
0 1 2
Model for use at initiation of therapy (N231)
ARF present N (weighted %) 24 (15) 30 (28) 37 (54)
Normal N (weighted %) 77 (85) 45 (72) 18 (46)
Risk score
0 1–3 4–7 8
Model for use during amphotericin course (N231)
ARF present N (weighted %) 1 (4) 15 (13) 54 (33) 21 (80)
Normal N (weighted %) 15 (96) 58 (87) 64 (67) 3 (20)
Example: Based on the first model, an ICU patient (1 point) already on cyclosporine (1 point) just beginning amphotericin B therapy would have risk score of 2
and 54% probability of developing ARF during hospital stay, while based on the second model, if this patient was given a dosage of 60 mg daily (5 points), the
patient would have risk score of 9 (ICU  2 points, cyclosporine use  2 points, plus the 5 points) and 80% probability of developing ARF.
Table 7. Projected costs of amphotericin B therapy
Risk score
Conventional amphotericin B therapy 0 1–3 4–7 8 or more
Expected incidence of ARF % 4.0 13.0 33.0 80.0
Expected length of hospital stay after therapy days 19 19 21 25
Expected cost of drug US$ 74 77 84 101
Expected marginal cost of ARF US$ 1193 3877 9842 23858
Expected total hospital cost US$ 72781 75465 81430 95446
ARF is acute renal failure. Length of hospital stay, total hospital cost and total dose estimates for ARF vs. no ARF are based on Bates et al [2]. We used US
$4.48 per 50 mg of amphotericin B as the cost of the drug, which is the cost to our hospital.
including 10% of patients with a risk of ARF of 80% included in the primary models entered the bootstrap-
derived models most frequently. The stability of the co-(Fig. 2). Both models fit well based on the Hosmer-
Lemeshow goodness-of-fit statistic [P  0.84 for the efficient estimates for both models also was evaluated,
and there was little difference for patient location orsmaller model (2 degrees of freedom) and P  0.34 for
the larger model (5 degrees of freedom)]. receipt of cyclosporine in either the beta coefficients or
the standard errors (data not shown). For the maximumIn the bootstrap validations for both the initiation
and during therapy rules, the same variables actually daily amphotericin dose, the 	 coefficents were larger,
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Fig. 2. Receiver operating characteristic (ROC)
for the prediction rule for ARF at the begin-
ning of (A) and during (B) amphotericin B
therapy. The areas under the curve were 0.69
and 0.73, respectively.
but standard errors also were larger: for amphotericin study is its larger sample size and the development of
prediction rules.dosage 30 to 59 mg, 	  1.39  0.59 in the initial model
versus 1.66  1.55 in the bootstrap validation; and for The prediction rules allow stratification of patients
into groups according to their risk of developing nephro-60 mg 	 2.17 0.62 in the initial model versus 2.46
1.58 in the bootstrap validation. These data suggest that toxicity and can be used to anchor estimates of probabil-
ity based on clinical experience. The model includingthe point estimates of the odds ratios from amphotericin
dosage are less stable than the other point estimates. maximum daily amphotericin dosage performs better,
but often this information is not known at the initiation
of therapy. However, for a patient in intensive care who
DISCUSSION is receiving cyclosporine and is anticipated to require
These data suggest that ARF occurs in about a quarter 60 mg/day of amphotericin, the risk of nephrotoxicity is
of the patients receiving amphotericin B and that higher clearly very high.
dosage and longer duration of therapy are associated We previously found that in adjusted analyses the av-
with a higher risk of nephrotoxicity, as are a higher level erage mortality was 54% when ARF developed versus
of care at onset and concomitant use of cyclosporine. only 16% when it did not, and the mean increase in total
However, baseline renal insufficiency was not correlated costs when ARF occurred was approximately $30,000
with a higher risk of ARF. [2]. Based on these data, the costs of amphotericin B
The data from Luber et al [10] and Fisher et al [9] therapy were projected in a patient beginning therapy
represent the best prior information about risk factors according to risk of ARF (Table 7). These data show
for amphotericin nephrotoxicity. Luber et al found that that the expected cost of ARF varies substantially by
greater cumulative dose of amphotericin B, and use of risk group from $1193 in the low-risk group to $23,858
concomitant nephrotoxins (including acyclovir, amino- in the highest risk group. While these data are projec-
glycosides, carboplatin, cisplatin, cyclosporine, foscarnet, tions, they illustrate how risk data may be useful in identi-
furosemide, nonsteroidal antiinflammatory agents, radio- fying patients who may benefit from alternatives to am-
contrast dye, rifampicin, intravenous trimethoprim-sul- photericin B. They also illustrate that the cost benefits
famethoxazole, tacrolimus, and vancomycin) were asso- of more expensive, but less nephrotoxic, anti-fungal agents
are most pronounced for high-risk patients. Dependingciated with increased risk of nephrotoxicity for several
definitions of nephrotoxicity. In addition, cyclosporine was on the specific cost of these agents, their use may increase
the total costs of hospitalization for lower risk patients.the strongest predictor of severe nephrotoxicity. Fisher’s
group found that amphotericin dose, patient weight, use Our study has a number of limitations. It was per-
formed at a single tertiary care center so that the resultsof diuretic therapy, and baseline renal dysfunction were
independently correlated with development of nephro- may not be generalizable to other settings. Confounding
by indication for initiating amphotericin therapy as welltoxicity. However, in this study, use of diuretic therapy
and baseline renal dysfunction were not correlated with as severity of illness may exist because the study is not
a randomized trial. If secular trends were present indevelopment of nephrotoxicity, and while there was a
univariate relationship between weight and nephrotoxic- terms of risk for developing ARF over the study period,
our sampling approach could have affected the results,ity, this variable was not retained in the repeated multi-
variate models. One important advantage of the current although the ARF rates were similar in the two periods
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